These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 27815174)
21. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. B A; D N; Veerabrahma K Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):126-137. PubMed ID: 28290712 [TBL] [Abstract][Full Text] [Related]
22. Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation. Jadhav P; Gokarna V; Deshpande V; Vavia P AAPS PharmSciTech; 2020 Sep; 21(7):254. PubMed ID: 32888102 [TBL] [Abstract][Full Text] [Related]
23. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hazan L; Hernández Rodriguez OA; Bhorat AE; Miyazaki K; Tao B; Heyrman R; Hypertension; 2010 Jun; 55(6):1323-30. PubMed ID: 20385971 [TBL] [Abstract][Full Text] [Related]
24. Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. Chae JW; Baek IH; Seo JW; Jung SH; Back HM; Song BJ; Lee BY; Yun HY; Kang W; Kwon KI Int J Clin Pharmacol Ther; 2014 Aug; 52(8):676-83. PubMed ID: 24849193 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: safety profiling. Nandi U; Karmakar S; Das AK; Ghosh B; Padman A; Chatterjee N; Pal TK Regul Toxicol Pharmacol; 2013 Feb; 65(1):68-78. PubMed ID: 23201407 [TBL] [Abstract][Full Text] [Related]
26. Oil based nanocarrier for improved oral delivery of silymarin: In vitro and in vivo studies. Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S Int J Pharm; 2011 Jul; 413(1-2):245-53. PubMed ID: 21549187 [TBL] [Abstract][Full Text] [Related]
27. Development and bioavailability assessment of ramipril nanoemulsion formulation. Shafiq S; Shakeel F; Talegaonkar S; Ahmad FJ; Khar RK; Ali M Eur J Pharm Biopharm; 2007 May; 66(2):227-43. PubMed ID: 17127045 [TBL] [Abstract][Full Text] [Related]
28. [A novel synthesis of olmesartan medoxomil and examination of its related impurities]. Wu TZ; Liu XH; Zhang FL; Xie MH Yao Xue Xue Bao; 2006 Jun; 41(6):537-43. PubMed ID: 16927829 [TBL] [Abstract][Full Text] [Related]
29. Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. Sengupta P; Das A; Ibrahim F; Mandal UK; Chatterjee B; Mahmood S; Das SK; Kifayatullah M Regul Toxicol Pharmacol; 2016 Nov; 81():155-161. PubMed ID: 27569202 [TBL] [Abstract][Full Text] [Related]
30. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake. Jones MR; Sealey JE; Laragh JH Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042 [TBL] [Abstract][Full Text] [Related]
31. Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Sengupta P; Nandi U; Pal TK Regul Toxicol Pharmacol; 2012 Feb; 62(1):7-15. PubMed ID: 22203042 [TBL] [Abstract][Full Text] [Related]
32. Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati D; Kotakonda HK; Yellu N Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):573-581. PubMed ID: 27535556 [TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan. Chang JS; El-Gamal MI; Lee WS; Anbar HS; Chung HJ; Kim HI; Cho YJ; Lee BS; Lee SA; Moon JY; Lee DJ; Jeon HR; Lee J; Choi YW; Oh CH Eur J Med Chem; 2011 Sep; 46(9):3564-9. PubMed ID: 21641692 [TBL] [Abstract][Full Text] [Related]
34. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Albash R; Abdelbary AA; Refai H; El-Nabarawi MA Int J Nanomedicine; 2019; 14():1953-1968. PubMed ID: 30936696 [TBL] [Abstract][Full Text] [Related]
35. Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model. Komesli Y; Ergur BU; Karasulu E Curr Drug Deliv; 2021; 18(10):1515-1525. PubMed ID: 34225629 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. Tanaka H; Nagasawa Y; Matsui I; Hamano T; Iwatani H; Kawada N; Horio M; Ito T; Isaka Y; Imai E Clin Exp Nephrol; 2009 Feb; 13(1):61-5. PubMed ID: 18574553 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. Jiang J; Liu D; Hu P Pharmazie; 2009 May; 64(5):323-6. PubMed ID: 19530443 [TBL] [Abstract][Full Text] [Related]
38. Nanocolloidal lipidic carriers of olmesartan medoxomil surface-tailored with Concavalin-A for lectin receptor targeting. Beg S; Choudhry H; Zamzami MA; Alharbi KS; Rahman M; Singh B Nanomedicine (Lond); 2018 Dec; 13(24):3107-3128. PubMed ID: 30474494 [TBL] [Abstract][Full Text] [Related]
39. The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Li KY; Liang JP; Hu BQ; Qiu Y; Luo CH; Jiang Y; Lin XP; Yang N Clin Ther; 2010 Aug; 32(9):1674-80. PubMed ID: 20974325 [TBL] [Abstract][Full Text] [Related]
40. Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Gardner SF; Franks AM Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]